TIDMRUA
RNS Number : 1026W
RUA Life Sciences PLC
08 December 2023
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR
INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO OR WITHIN THE UNITED
STATES, AUSTRALIA, NEW ZEALAND, CANADA, SOUTH AFRICA OR JAPAN, OR
ANY MEMBER STATE OF THE EEA, OR ANY OTHER JURISDICTION WHERE, OR TO
ANY OTHER PERSON TO WHOM, TO DO SO MIGHT CONSTITUTE A VIOLATION OR
BREACH OF ANY APPLICABLE LAW OR REGULATION. PLEASE SEE THE
IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES
OF THE MARKET ABUSE REGULATION (EU) 596/2014 WHICH FORMS PART OF UK
LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("UK
MAR").
8 December 2023
RUA LIFE SCIENCES PLC
("RUA Life Sciences", the "Company" or the "Group")
Result of Retail Offer
Further to the announcement dated 30 November 2023, RUA Life
Sciences plc (AIM: RUA.L), the holding company of a group of
medical device businesses focused on the exploitation of
Elast-Eon(TM), the world leading long-term implantable biostable
polyurethane, is pleased to announce that, following the closing of
the Retail Offer on the BookBuild platform on 7 December 2023,
2,784,566 Ordinary Shares will be issued at the Issue Price of 11
pence per Retail Offer Share in connection with the Retail Offer,
raising an additional GBP0.31 million.
Consequently, conditional on the passing of the Resolutions at
the General Meeting (and, in relation to the Subscription Shares
only, the announcement of Group's interim accounts ending the
closed period), 36,363,636 Placing Shares, 727,272 Subscription
Shares and 2,784,566 Retail Offer Shares, resulting in a total of
39,875,474 new Ordinary Shares, will be issued in relation to the
Placing, Subscription and Retail Offer, raising total gross
proceeds of GBP4.4 million.
Admission and Total Voting Rights
Application has been made for the Retail Offer Shares to be
admitted to trading on AIM ("Admission"). Admission is expected to
take place at 8.00 a.m. on or around 19 December 2023.
The Retail Offer Shares will, when issued, be credited as fully
paid up and will have the same rights as the Existing Ordinary
Shares including, voting, dividend, return of capital and other
rights, and will on issue be free of all claims, liens, charges,
encumbrances and equities.
Following Admission, the total number of Ordinary Shares in the
capital of the Company in issue will be 62,060,272 with each
Ordinary Share carrying the right to one vote. There are no shares
held in treasury and therefore, following Admission, the total
number of voting rights in the Company will be 62,060,272. The
above figure may be used by Shareholders as the denominator for the
calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, the
share capital of the Company under the FCA's Disclosure, Guidance
and Transparency Rules.
Capitalised terms used in this announcement have the meaning
given to them in the Placing and Retail Offer announcement dated 30
November 2023, unless otherwise defined in this announcement.
For further information contact:
RUA Life Sciences
Bill Brown, Chairman Tel: +44 (0)1294 317073
Caroline Stretton, Group Managing Tel: +44 (0)1294 317073
Director
Cavendish Capital Markets Limited Tel: +44 (0)20 7220 0500
(Nominated Adviser and Broker)
Giles Balleny/Dan Hodkinson (Corporate
Finance)
Charlie Combe (ECM)
Michael Johnson (Sales)
About RUA Life Sciences
The RUA Life Sciences group was created in April 2020 when RUA
Life Sciences Plc (formerly known as AorTech International Plc)
acquired RUA Medical Devices Limited to create a fully formed
medical device business. RUA Life Sciences is the holding company
of the Group's four trading businesses, each exploiting the Group's
patented polymer technology.
Our vision is to improve the lives of millions of patients by
enabling medical devices with Elast-Eon (TM) , the world's leading
long-term implantable polyurethane. Whether it is licensing
Elast-Eon (TM) , manufacturing a device or component, or developing
next generation medical devices, a RUA Life Sciences business is
pursuing our vision.
Elast-Eon(TM)'s biostability is comparable to silicone while
exhibiting excellent mechanical, blood contacting and flex-fatigue
properties. These polymers can be processed using conventional
thermoplastic extrusion and moulding techniques. With over 8
million implants and 15 years of successful clinical use, RUA's
polymers are proven in long-term life enabling applications.
The Group's four business units are:
RUA Contract End-to-end contract developer and manufacturer
Manufacture: of medical devices and implantable fabric
specialist.
RUA Biomaterials: Licensor of Elast-Eon (TM) polymers to the
medical device industry.
RUA Vascular: Commercialisation of open surgical vascular
grafts and patches
RUA Structural Development of polymeric leaflet systems for
Heart: heart valves.
This announcement should be read in its entirety. In particular,
the information in the "Important Notices" section of the
announcement should be read and understood.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ROIEANAXEANDFFA
(END) Dow Jones Newswires
December 08, 2023 02:00 ET (07:00 GMT)
Rua Life Sciences (LSE:RUA)
過去 株価チャート
から 4 2024 まで 5 2024
Rua Life Sciences (LSE:RUA)
過去 株価チャート
から 5 2023 まで 5 2024
